Provided by Tiger Trade Technology Pte. Ltd.

Biocryst Pharmaceuticals

9.55
-0.1100-1.14%
Post-market: 9.660.1099+1.15%19:30 EDT
Volume:2.50M
Turnover:24.02M
Market Cap:2.44B
PE:-6.34
High:9.91
Open:9.72
Low:9.48
Close:9.66
52wk High:11.22
52wk Low:6.00
Shares:255.54M
Float Shares:222.00M
Volume Ratio:0.94
T/O Rate:1.12%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5054
EPS(LYR):1.21
ROE:587.33%
ROA:52.86%
PB:-5.37
PE(LYR):7.89

Loading ...

How Investors May Respond To BioCryst (BCRX) Profit Swing, Raised Revenue Outlook And New ESOP Shares

Simply Wall St.
·
Aug 15

BioCryst Pharmaceuticals (BCRX) Could Be 54% Undervalued Following Strong Earnings Guidance

Simply Wall St.
·
Aug 12

SIGA Technologies Q2 Revenue, Profit Drop as Contract Ends

Reuters
·
Aug 07

BioCryst Pharmaceuticals Price Target Cut to $20.00/Share from $21.00 by Wedbush

Dow Jones
·
Aug 07

Cancer Drugmaker Genmab's H1 Revenue Rises, Lifts FY Outlook

Reuters
·
Aug 06

Zevra Therapeutics Q2 Revenue Rises 53% on Miplyffa Sales

Reuters
·
Aug 06

Sarepta Q2 Results Beat Expectations Despite Lower Sales Stemming from Elevidys Relabel, Unmet Roche Milestone

Reuters
·
Aug 06

Emergent BioSolutions Swings to Q2 Loss on Impairment Charge; to Cut Jobs

Reuters
·
Aug 06

Wedbush Adjusts BioCryst Pharmaceuticals Price Target to $20 From $21, Maintains Outperform Rating

MT Newswires Live
·
Aug 06

BioCryst Pharmaceuticals Q2 Earnings, Revenue Increase; 2026 Revenue Outlook Raised

MT Newswires Live
·
Aug 05

BioCryst Pharmaceuticals, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 05

UroGen Pharma Q2 Revenue Beats on Strong Zusduri Sales

Reuters
·
Aug 05

Earnings Flash (BCRX) BioCryst Pharmaceuticals Posts Q2 EPS $0.30, vs. FactSet Est of $0.15

MT Newswires Live
·
Aug 05

BioCryst Pharma Q2 EPS $0.30, Sales $218.250M Beat $182.514M Estimate

Benzinga Earnings
·
Aug 05

BioCryst Pharmaceuticals Outlook FY Sales USD 690-715 Million

THOMSON REUTERS
·
Aug 05

BioCryst Pharmaceuticals Q2 EPS USD 0.3

THOMSON REUTERS
·
Aug 05

BioCryst Pharmaceuticals, - Cash, Cash Equivalents, Restricted Cash and Investments $354 Mln at June 30, 2026

THOMSON REUTERS
·
Aug 05

BioCryst Pharmaceuticals - Expects Additional Costs for Discovery Center Closure; Analysis Ongoing - SEC Filing

THOMSON REUTERS
·
Aug 04

BioCryst Pharmaceuticals - Estimates $6.2-$7.50 Mln in One-Time Expenses for Termination Benefits, $5.3-$6.60 Mln Cash - SEC Filing

THOMSON REUTERS
·
Aug 04

BioCryst Amends 8-K, Estimates $6.2 Million-$7.5 Million in One-Time Severance Costs for Discovery Shutdown Plan

Reuters
·
Aug 04